| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,413,000 |
| Market
Cap: |
8.67(B) |
| Last
Volume: |
854,657 |
Avg
Vol: |
504,733 |
| 52
Week Range: |
$114.17 - $208.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
23,589 |
45,669 |
50,307 |
151,828 |
| Total Sell Value |
$4,058,631 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
| Total People Sold |
2 |
4 |
5 |
6 |
| Total Sell Transactions |
2 |
5 |
7 |
17 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barthelemy Nicholas |
Director |
– • – |
2020-04-22 |
4 |
OE |
$42.07 |
$69,500 |
D/D |
1,652 |
5,725 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2020-04-21 |
4 |
OE |
$3.30 |
$38,940 |
D/D |
11,800 |
120,834 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2020-04-20 |
4 |
AS |
$104.42 |
$1,275,717 |
D/D |
(12,200) |
109,034 |
|
44% |
|
| Dawes Karen A |
Director |
– • – |
2020-04-20 |
4 |
OE |
$3.30 |
$27,060 |
D/D |
8,200 |
121,234 |
|
- |
|
| Barthelemy Nicholas |
Director |
– • – |
2020-04-03 |
4 |
AS |
$99.99 |
$268,773 |
D/D |
(2,688) |
4,073 |
|
51% |
|
| Barthelemy Nicholas |
Director |
– • – |
2020-04-03 |
4 |
OE |
$42.07 |
$69,500 |
D/D |
1,652 |
6,761 |
|
- |
|
| Cox John |
Director |
– • – |
2020-03-24 |
4 |
S |
$96.72 |
$179,706 |
D/D |
(1,858) |
923 |
|
-67% |
|
| Cox John |
Director |
– • – |
2020-03-18 |
4 |
S |
$95.13 |
$2,547,035 |
D/D |
(26,736) |
2,781 |
|
-42% |
|
| Cox John |
Director |
– • – |
2020-03-18 |
4 |
OE |
$12.91 |
$651,603 |
D/D |
26,736 |
29,517 |
|
- |
|
| Ryan Thomas F Jr |
Director |
– • – |
2020-03-16 |
4 |
S |
$91.48 |
$91,480 |
D/D |
(1,000) |
1,923 |
|
-54% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2020-03-16 |
4 |
OE |
$38.76 |
$40,415 |
D/D |
1,000 |
2,923 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2020-03-04 |
4 |
S |
$90.39 |
$94,458 |
D/D |
(1,045) |
36,127 |
|
-33% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2020-03-04 |
4 |
S |
$90.13 |
$1,108,599 |
D/D |
(12,300) |
230,241 |
|
-33% |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2020-03-04 |
4 |
S |
$90.08 |
$231,888 |
D/D |
(2,555) |
26,524 |
|
-33% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2020-03-04 |
4 |
S |
$88.82 |
$425,981 |
D/D |
(4,796) |
1,923 |
|
-33% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2020-03-04 |
4 |
OE |
$41.19 |
$200,015 |
D/D |
4,796 |
6,719 |
|
- |
|
| Cox John |
Director |
– • – |
2020-03-04 |
4 |
S |
$93.39 |
$933,900 |
D/D |
(10,000) |
2,781 |
|
-33% |
|
| Cox John |
Director |
– • – |
2020-03-04 |
4 |
OE |
$12.91 |
$129,100 |
D/D |
10,000 |
12,781 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2020-03-03 |
4 |
S |
$88.18 |
$53,790 |
D/D |
(610) |
37,172 |
|
-41% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2020-03-03 |
4 |
S |
$88.20 |
$193,194 |
D/D |
(2,190) |
242,541 |
|
-41% |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2020-03-03 |
4 |
S |
$88.35 |
$39,758 |
D/D |
(450) |
29,079 |
|
-41% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2020-03-03 |
4 |
S |
$85.72 |
$190,727 |
D/D |
(2,225) |
1,923 |
|
-41% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
18,583 |
244,731 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,686 |
37,782 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
3,216 |
29,529 |
|
- |
|
647 Records found
|
|
Page 11 of 26 |
|
|
4.55 (3.12%) 
